Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-Operative Atezolizumab for Resectable HPV-Related OPSCC
NCT06254911Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Emory University. Primary endpoints: Incidence of treatment-emergent adverse events, Pathologic response and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT06254911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254911.